Keros Therapeutics 将来の成長

Future 基準チェック /06

Keros Therapeuticsの収益と利益はそれぞれ年間16.4%と29.2%減少すると予測されていますが、EPS は年間26.3% 減少すると予測されています。

主要情報

-29.2%

収益成長率

-26.31%

EPS成長率

Biotechs 収益成長	22.8%
収益成長率	-16.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	10 Mar 2026

今後の成長に関する最新情報

Recent updates

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Nov 18

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Aug 21

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

May 29

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

May 14

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

May 09

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

業績と収益の成長予測

NasdaqGM:KROS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	54	-144	-142	N/A	8
12/31/2027	11	-159	-145	N/A	8
12/31/2026	3	-134	-109	N/A	8
12/31/2025	244	87	106	108	N/A
9/30/2025	247	64	87	89	N/A
6/30/2025	233	19	53	55	N/A
3/31/2025	215	4	43	45	N/A
12/31/2024	4	-187	-163	-161	N/A
9/30/2024	1	-182	-143	-140	N/A
6/30/2024	0	-168	-146	-144	N/A
3/31/2024	0	-160	-137	-135	N/A
12/31/2023	0	-153	-127	-125	N/A
9/30/2023	0	-142	-123	-120	N/A
6/30/2023	N/A	-127	-113	-111	N/A
3/31/2023	N/A	-116	-105	-103	N/A
12/31/2022	N/A	-105	-71	-70	N/A
9/30/2022	20	-82	-69	-68	N/A
6/30/2022	20	-79	-59	-58	N/A
3/31/2022	20	-67	-54	-53	N/A
12/31/2021	20	-59	-63	-62	N/A
9/30/2021	0	-61	-51	-51	N/A
6/30/2021	0	-53	-48	-47	N/A
3/31/2021	N/A	-49	-40	-39	N/A
12/31/2020	N/A	-45	-37	-37	N/A
9/30/2020	3	-39	-35	-34	N/A
6/30/2020	5	-31	-27	-26	N/A
3/31/2020	8	-23	-22	-22	N/A
12/31/2019	10	-14	-16	-16	N/A
12/31/2018	10	-2	N/A	7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: KROSの収益は今後 3 年間で減少すると予測されています (年間-29.2% )。

収益対市場: KROSの収益は今後 3 年間で減少すると予測されています (年間-29.2% )。

高成長収益: KROSの収益は今後 3 年間で減少すると予測されています。

収益対市場: KROSの収益は今後 3 年間で減少すると予想されています (年間-16.4% )。

高い収益成長: KROSの収益は今後 3 年間で減少すると予測されています (年間-16.4% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: KROSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/03/12 17:18
終値	2026/03/12 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成する分析モデルの詳細は当社の Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや YouTubeのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Keros Therapeutics, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。17

アナリスト	機関
Jason Zemansky	BofA Global Research
Corinne Johnson	Goldman Sachs
Andrew Fein	H.C. Wainwright & Co.

Keros Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 7.1% to US$88.11

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Consensus EPS estimates fall by 18%

Price target increased to US$98.75

Price target increased to US$94.00

Recent updates

Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program

Keros Therapeutics, Inc. Promotes Esther Cho as Chief Legal Officer, Effective February 24, 2026

Keros Therapeutics, Inc. Announces Board Changes, Effective March 9, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. (NasdaqGM:KROS) announces an Equity Buyback for 10,950,165 shares, representing 35.94% for $194.37 million.

Keros Therapeutics, Inc. Announces Board and Committee Changes, Effective October 15, 2025

Keros Therapeutics, Inc. Presents Additional Clinical Data from Its Ker-065 Program At the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

ADAR1 Sends Open Letter to Keros Board of Directors

Keros Therapeutics, Inc. Announces Management Changes, Effective August 18, 2025

Keros Therapeutics, Inc. Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Growth Index

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Keros Therapeutics, Inc. Announces Corporate Restructuring

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics, Inc., Annual General Meeting, Jun 04, 2025

Keros Therapeutics, Inc. Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock